PDF(Pubmed)
Abstract：
The COVID-19 pandemic has caused havoc in the health sector. Inflammatory cytokines play an important role in the disease condition. Existing evidence has provided certain insights into the repurposing of the drugs. This meta-analysis and systematic review aimed to explore the efficacy of the administration of interferon beta-1b (IFN β-1b) and standard care versus only standard care as the therapeutic agent for managing COVID-19 patients who are severely ill. The search was conducted in the following databases: Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Scopus, and Google Scholar, which were published during the period January 1, 2020, to February 16, 2023. All the included three studies were independently assessed for eligibility. The modified data extraction form of Cochrane were used. The quality of the three included studies was assessed using the Cochrane risk of bias tool. GradePro software was used to summarize the quality grading of the primary outcome measures. The time taken for clinical improvement was (MD: -3.28 days; 95% CI: -5.65, -0.91; P value = 0.007) when treated with IFN β-1b. The duration of hospital stays (MD: -2.43 days; 95% CI: -4.45, -0.30; P value = 0.03), and need for intensive care unit (ICU) admission (RR: 0.71; 95% CI: 0.52, 0.97; P value = 0.03) was statistically significant. Interferon beta-1b is proven to reduce the duration of hospital stay, and the improved clinical status may become a cornerstone of COVID-19 treatment.
摘要：
COVID-19大流行在卫生部门造成了严重破坏。炎性细胞因子在疾病状态中起着重要作用。现有证据为药物的再利用提供了一些见解。这项荟萃分析和系统评价旨在探讨干扰素β-1b（IFNβ-1b）和标准治疗与仅标准治疗作为治疗重症COVID-19患者的治疗药物的疗效。在以下数据库中进行搜索：Cochrane中央对照试验登记册（CENTRAL），PubMed,Scopus,和谷歌学者，在2020年1月1日至2023年2月16日期间发布。所有纳入的三项研究均独立评估合格性。采用修改后的Cochrane数据提取形式。使用Cochrane偏倚风险工具评估三项纳入研究的质量。GradePro软件用于总结主要结局指标的质量分级。用IFNβ-1b治疗时，临床改善所需的时间为（MD：-3.28天；95％CI：-5.65，-0.91；P值=0.007）。住院时间(MD:-2.43天;95%CI:-4.45,-0.30;P值=0.03),和重症监护病房（ICU）的需要（RR：0.71;95％CI：0.52,0.97;P值=0.03）有统计学意义。干扰素β-1b被证明可以减少住院时间，临床状况的改善可能成为COVID-19治疗的基石。
